Clinical response in osteogenic sarcoma patients treated with ultra-dilute medicines

Osteogenic sarcoma management is a challenge for the cancer community globally. Not much awareness or information about the use of complementary and alternative medicine (CAM), more specifically treatment with ultra-dilute medicines, is available for such cases. Our experience in this will show that treatment of this dreaded disease with ultra-dilute medicines can be considered as a possible option. This treatment has been well tested in the clinical setting, by virtue of it being in use for decades with a good degree of success. This has inspired us to follow closely data available at our institution clinics where we treat this disease by using the “Banerji Protocols”. These protocols consist of the use of disease specific ultra-dilute medicines in specific dilutions, in pre-set dosage patterns. By this conservative treatment, surgical interventions such as amputation of affected parts can be avoided and the patient returned to health. Recent experimental studies of “Banerji Protocol” medicines used in cancer treatment have revealed that these medicines act both at the molecular as well as the genetic levels resulting in growth arrest and apoptosis in tumor cells. The findings suggest that such tumor cell specific cytostatic and cytotoxic effects could be responsible for the observed therapeutic efficacy of these medicines in cancer treatment. Correspondence to: Dr. Prasanta Banerji, PBH Research Foundation, 10/3/1 Elgin Road, Kolkata–700020, India, Tel: + 91 33 30582818; Fax: + 91 33 22877275; Email: [email protected]; [email protected] Dr. Pratip Banerji, PBH Research Foundation, 10/3/1 Elgin Road, Kolkata–700020, India, Tel: + 91 33 30582818; Fax: + 91 33 22877275; E-mail: [email protected]; [email protected]